Tg Therapeutics Stock Retained Earnings

TGTX Stock

USD 35.07 0.52 1.51%

TG Therapeutics fundamentals help investors to digest information that contributes to TG Therapeutics' financial success or failures. It also enables traders to predict the movement of TGTX Stock. The fundamental analysis module provides a way to measure TG Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to TG Therapeutics stock.

	Last Reported	Projected for Next Year
Retained Earnings	-1.5 B	-1.4 B
Retained Earnings Total Equity	-1.4 B	-1.3 B

Retained Earnings is likely to rise to about (1.4 B) in 2024. Retained Earnings Total Equity is likely to rise to about (1.3 B) in 2024.

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

TG Therapeutics Company Retained Earnings Analysis

TG Therapeutics' Retained Earnings is a balance sheet account that refers to the portion of company income that is retained by the firm. In other words, it is a part of earnings that is not paid out as dividends or otherwise distributed to owners. Retained Earnings are calculated by adding net income to last period retained earnings and subtracting any dividends paid to owners.

Retained Earnings

Beginning RE + Income

-

Dividends

More About Retained Earnings | All Equity Analysis

Current TG Therapeutics Retained Earnings

(1.51 B)

Most of TG Therapeutics' fundamental indicators, such as Retained Earnings, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, TG Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

TGTX Retained Earnings Driver Correlations

Understanding the fundamental principles of building solid financial models for TG Therapeutics is extremely important. It helps to project a fair market value of TGTX Stock properly, considering its historical fundamentals such as Retained Earnings. Since TG Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of TG Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of TG Therapeutics' interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Total Liab	Total Current Assets	Net Receivables	Accounts Payable	Common Stock	Property Plant Equipment	Short Term Investments	Long Term Debt	Short Term Debt	Current Deferred Revenue	Intangible Assets	Net Tangible Assets	Good Will	Long Term Debt Total	Capital Surpluse	Deferred Long Term Liab	Treasury Stock	Long Term Investments	Short Long Term Debt	Net Invested Capital	Net Working Capital	Capital Stock
Total Assets		-0.03	-0.74	-0.75	0.69	1.0	0.39	0.52	-0.08	0.76	0.59	0.52	0.82	-0.01	-0.36	0.88	0.47	0.46	0.84	-0.39	-0.43	0.04	0.75	0.96	0.96	0.84
Total Stockholder Equity	-0.03		-0.07	0.44	-0.29	0.02	0.22	-0.02	-0.05	-0.34	0.09	-0.37	0.17	-0.27	0.1	0.03	0.01	-0.42	-0.31	0.28	0.16	-0.47	0.3	0.06	0.11	-0.38
Net Debt	-0.74	-0.07		0.21	-0.16	-0.75	0.27	-0.13	0.05	-0.5	0.05	0.14	-0.92	0.0	0.19	-0.94	-0.05	0.18	-0.31	0.09	0.27	-0.12	-0.91	-0.81	-0.8	-0.35
Retained Earnings	-0.75	0.44	0.21		-0.85	-0.74	-0.6	-0.7	0.05	-0.77	-0.79	-0.91	-0.34	-0.05	0.37	-0.42	-0.59	-0.87	-0.98	0.47	0.45	-0.03	-0.24	-0.61	-0.61	-0.96
Total Liab	0.69	-0.29	-0.16	-0.85		0.67	0.6	0.64	-0.32	0.61	0.79	0.77	0.21	0.18	-0.57	0.38	0.75	0.86	0.86	-0.26	-0.7	0.18	0.13	0.48	0.48	0.79
Total Current Assets	1.0	0.02	-0.75	-0.74	0.67		0.4	0.54	-0.07	0.74	0.61	0.51	0.83	-0.01	-0.35	0.88	0.47	0.43	0.83	-0.38	-0.42	-0.01	0.78	0.96	0.96	0.83
Net Receivables	0.39	0.22	0.27	-0.6	0.6	0.4		0.48	0.0	0.29	0.91	0.79	-0.04	-0.1	-0.15	-0.01	0.57	0.7	0.64	-0.38	-0.12	-0.27	-0.06	0.3	0.32	0.57
Accounts Payable	0.52	-0.02	-0.13	-0.7	0.64	0.54	0.48		-0.19	0.49	0.76	0.58	0.34	0.18	-0.41	0.19	0.57	0.55	0.7	-0.07	-0.51	-0.5	0.32	0.35	0.38	0.59
Common Stock	-0.08	-0.05	0.05	0.05	-0.32	-0.07	0.0	-0.19		0.12	-0.11	0.01	0.02	-0.05	0.9	-0.06	-0.71	-0.14	-0.06	-0.67	0.73	-0.09	0.03	0.05	0.04	0.04
Property Plant Equipment	0.76	-0.34	-0.5	-0.77	0.61	0.74	0.29	0.49	0.12		0.46	0.58	0.48	0.08	-0.15	0.63	0.34	0.58	0.78	-0.31	-0.39	0.01	0.4	0.69	0.67	0.75
Short Term Investments	0.59	0.09	0.05	-0.79	0.79	0.61	0.91	0.76	-0.11	0.46		0.84	0.2	-0.05	-0.33	0.18	0.69	0.8	0.83	-0.35	-0.37	-0.26	0.16	0.45	0.48	0.74
Long Term Debt	0.52	-0.37	0.14	-0.91	0.77	0.51	0.79	0.58	0.01	0.58	0.84		0.02	0.01	-0.26	0.11	0.56	0.92	0.88	-0.5	-0.28	0.0	-0.08	0.37	0.37	0.84
Short Term Debt	0.82	0.17	-0.92	-0.34	0.21	0.83	-0.04	0.34	0.02	0.48	0.2	0.02		-0.05	-0.15	0.9	0.1	-0.09	0.45	-0.26	-0.18	-0.12	0.99	0.88	0.89	0.5
Current Deferred Revenue	-0.01	-0.27	0.0	-0.05	0.18	-0.01	-0.1	0.18	-0.05	0.08	-0.05	0.01	-0.05		-0.1	-0.12	0.04	-0.03	0.01	-0.1	-0.14	-0.19	-0.08	-0.14	-0.14	0.04
Intangible Assets	-0.36	0.1	0.19	0.37	-0.57	-0.35	-0.15	-0.41	0.9	-0.15	-0.33	-0.26	-0.15	-0.1		-0.25	-0.76	-0.38	-0.38	-0.39	0.81	-0.09	-0.11	-0.2	-0.2	-0.29
Net Tangible Assets	0.88	0.03	-0.94	-0.42	0.38	0.88	-0.01	0.19	-0.06	0.63	0.18	0.11	0.9	-0.12	-0.25		0.2	0.09	0.53	-0.23	-0.33	0.22	0.86	0.92	0.91	0.56
Good Will	0.47	0.01	-0.05	-0.59	0.75	0.47	0.57	0.57	-0.71	0.34	0.69	0.56	0.1	0.04	-0.76	0.2		0.63	0.61	0.24	-0.78	-0.04	0.07	0.31	0.32	0.51
Long Term Debt Total	0.46	-0.42	0.18	-0.87	0.86	0.43	0.7	0.55	-0.14	0.58	0.8	0.92	-0.09	-0.03	-0.38	0.09	0.63		0.83	-0.33	-0.46	0.18	-0.18	0.27	0.26	0.75
Capital Surpluse	0.84	-0.31	-0.31	-0.98	0.86	0.83	0.64	0.7	-0.06	0.78	0.83	0.88	0.45	0.01	-0.38	0.53	0.61	0.83		-0.48	-0.45	0.01	0.35	0.71	0.71	0.97
Deferred Long Term Liab	-0.39	0.28	0.09	0.47	-0.26	-0.38	-0.38	-0.07	-0.67	-0.31	-0.35	-0.5	-0.26	-0.1	-0.39	-0.23	0.24	-0.33	-0.48		-0.39	-0.11	-0.19	-0.43	-0.42	-0.61
Treasury Stock	-0.43	0.16	0.27	0.45	-0.7	-0.42	-0.12	-0.51	0.73	-0.39	-0.37	-0.28	-0.18	-0.14	0.81	-0.33	-0.78	-0.46	-0.45	-0.39		-0.15	-0.15	-0.24	-0.24	-0.34
Long Term Investments	0.04	-0.47	-0.12	-0.03	0.18	-0.01	-0.27	-0.5	-0.09	0.01	-0.26	0.0	-0.12	-0.19	-0.09	0.22	-0.04	0.18	0.01	-0.11	-0.15		-0.17	0.03	-0.02	0.06
Short Long Term Debt	0.75	0.3	-0.91	-0.24	0.13	0.78	-0.06	0.32	0.03	0.4	0.16	-0.08	0.99	-0.08	-0.11	0.86	0.07	-0.18	0.35	-0.19	-0.15	-0.17		0.84	0.85	0.39
Net Invested Capital	0.96	0.06	-0.81	-0.61	0.48	0.96	0.3	0.35	0.05	0.69	0.45	0.37	0.88	-0.14	-0.2	0.92	0.31	0.27	0.71	-0.43	-0.24	0.03	0.84		1.0	0.76
Net Working Capital	0.96	0.11	-0.8	-0.61	0.48	0.96	0.32	0.38	0.04	0.67	0.48	0.37	0.89	-0.14	-0.2	0.91	0.32	0.26	0.71	-0.42	-0.24	-0.02	0.85	1.0		0.75
Capital Stock	0.84	-0.38	-0.35	-0.96	0.79	0.83	0.57	0.59	0.04	0.75	0.74	0.84	0.5	0.04	-0.29	0.56	0.51	0.75	0.97	-0.61	-0.34	0.06	0.39	0.76	0.75

Click cells to compare fundamentals

Retained Earnings shows how the firm utilizes its profits over time. In simple terms, investors can think of retained earnings as the amount of profit the company has reinvested in the business since its inceptions. However the methodology to make a decision over how much profit to retain is different between companies in different industries. For example, growing industries tend to retain more of their earnings than more matured industries as they need more assets investment to sustain their growth.

Competition

Predict TG Therapeutics

Retained Earnings Over Time

Based on the latest financial disclosure, TG Therapeutics has a Retained Earnings of (1.51 Billion). This is 262.6% lower than that of the Biotechnology sector and significantly lower than that of the Health Care industry. The retained earnings for all United States stocks is 116.23% higher than that of the company.

TGTX Retained Earnings Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses TG Therapeutics' direct or indirect competition against its Retained Earnings to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of TG Therapeutics could also be used in its relative valuation, which is a method of valuing TG Therapeutics by comparing valuation metrics of similar companies.

TG Therapeutics is currently under evaluation in retained earnings category among its peers.

TG Therapeutics Current Valuation Drivers

We derive many important indicators used in calculating different scores of TG Therapeutics from analyzing TG Therapeutics' financial statements. These drivers represent accounts that assess TG Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of TG Therapeutics' important valuation drivers and their relationship over time.

	2019	2020	2021	2022	2023	2024 (projected)
Market Cap	309.4M	980.9M	6.0B	1.6B	2.4B	2.5B
Enterprise Value	267.5M	909.1M	5.5B	1.6B	2.4B	2.6B

TG Therapeutics ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, TG Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to TG Therapeutics' managers, analysts, and investors.

Environmental

Governance

Social

TGTX Fundamentals

	Return On Equity	-0.0805
	Return On Asset	-7.0E-4
	Profit Margin	(0.05) %
	Operating Margin	0.15 %
	Current Valuation	4.76 B
	Shares Outstanding	155.66 M
	Shares Owned By Insiders	9.50 %
	Shares Owned By Institutions	66.32 %
	Number Of Shares Shorted	32 M
	Price To Earning	(4.14) X
	Price To Book	25.23 X
	Price To Sales	20.31 X
	Revenue	233.66 M
	Gross Profit	2.52 M
	EBITDA	21.06 M
	Net Income	12.67 M
	Cash And Equivalents	195.71 M
	Cash Per Share	1.45 X
	Total Debt	110.8 M
	Debt To Equity	0.62 %
	Current Ratio	4.68 X
	Book Value Per Share	1.34 X
	Cash Flow From Operations	(31.41 M)
	Short Ratio	13.37 X
	Earnings Per Share	(0.10) X
	Target Price	37.22
	Number Of Employees	319
	Beta	2.19
	Market Capitalization	5.38 B
	Total Asset	329.59 M
	Retained Earnings	(1.51 B)
	Working Capital	264.22 M
	Current Asset	71.33 M
	Current Liabilities	16.88 M
	Net Asset	329.59 M

About TG Therapeutics Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze TG Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of TG Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of TG Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

RSI	Rush Street Interactive
OKTA	Okta Inc
BAC	Bank of America

Additional Tools for TGTX Stock Analysis

When running TG Therapeutics' price analysis, check to measure TG Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy TG Therapeutics is operating at the current time. Most of TG Therapeutics' value examination focuses on studying past and present price action to predict the probability of TG Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move TG Therapeutics' price. Additionally, you may evaluate how the addition of TG Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC